Market Research Report
Germany Multiplex Assay Market Forecast 2021-2026
|Published by||Inkwood Research||Product code||1018664|
|Published||Content info||119 Pages
Delivery time: 2-3 business days
|Germany Multiplex Assay Market Forecast 2021-2026|
|Published: July 19, 2021||Content info: 119 Pages||
The Germany multiplex assay market is projected to register a CAGR of 8.90% over the forecast years. The developments within the pharmaceutical industry, as well as the partnerships and collaborations of clinical trials, are among the key factors associated with the market growth of the country. While the base year considered for the market study is 2020, the estimated period is from 2021 to 2026.
Multiplex assays deliver convenient, automated, and faster disease analysis, as compared to traditional methods. Moreover, they are largely used for mutation analysis, pathogen identification, gene detection analysis, forensic studies, RNA detection, linkage analysis, and others. Germany is one of the leading destinations for pharmaceutical research and development (R&D) globally. According to the 2019 report by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the country invested approximately EUR 6,918 million in pharmaceutical R&D in 2017. Hence, these aspects result in an increasing number of drug discoveries and developments, playing a vital role in fueling the country's demand for digital PCR technology. Furthermore, extensive research activities across the German pharmaceutical industry are set to fuel the usage of digital PCR, as well.
On the other hand, the government of Germany provides infrastructural support for domestic and foreign multinational companies in order to establish new manufacturing centers and expand existing R&D sites. Therefore, the abovementioned factors are evaluated to fuel the multiplex assay market growth in the country over the forecasting period.
Some of the leading enterprises operating in the market are: Siemens Healthineers AG, Agilent Technologies Inc, Qiagen NV, etc.